SCHEMBL4773623

SCHEMBL4773623

Cc1cccc(CCNc2cc(-c3cccnc3)nc(-c3ccccn3)n2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.48
CYP2C9 P11712 2/20 0.48
CYP2A6 P11509 2/20 0.46
PTGDR Q13258 3/20 0.46
GBA1 P04062 1/20 0.45
HIF1A Q16665 2/20 0.42
APP P05067 3/20 0.42
SLC2A1 P11166 1/20 0.42
CYP1A2 P05177 2/20 0.41
CLK4 Q9HAZ1 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2240945 0.90 GBA1 (0.54) CYP3A4CYP2C9CYP2A6PTGDRGBA1
SCHEMBL2237320 0.85 HIF1A (0.47) CYP3A4CYP2C9CYP2A6PTGDRGBA1
SCHEMBL2238098 0.83 PTGDR (0.53) CYP3A4CYP2C9CYP2A6PTGDRGBA1
SCHEMBL4774817 0.82 CYP3A4 (0.46) CYP3A4CYP2C9CYP2A6PTGDRGBA1
SCHEMBL4773528 0.82 PTGDR (0.43) CYP3A4CYP2C9CYP2A6PTGDRGBA1
SCHEMBL4769194 0.82 PTGDR (0.46) CYP3A4CYP2C9CYP2A6PTGDRGBA1
SCHEMBL2237967 0.81 CYP3A4 (0.47) CYP3A4CYP2C9CYP2A6PTGDRGBA1
SCHEMBL4771527 0.81 CYP3A4 (0.55) CYP3A4CYP2C9CYP2A6HIF1ASLC2A1
SCHEMBL2239349 0.80 CDK4 (0.47) CYP3A4CYP2C9PTGDRGBA1HIF1A
SCHEMBL4775854 0.80 METAP1 (0.47) CYP3A4CYP2C9CYP2A6PTGDRGBA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1878733-A1 Pyrimidine derivatives as ALK-5 inhibitors Novartis AG (CH) 2008-01-16 EP disclosed